Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG

La Mont J. Barlow; Catherine M. Seager; Mitchell C. Benson; James M. McKiernan

doi:10.1016/j.urolonc.2009.03.029

Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG

La Mont J. Barlow^*, Catherine M. Seager, Mitchell C. Benson, James M. McKiernan

^*Corresponding author for this work

Urology

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

The definitive treatment for patients with non-muscle-invasive bladder cancer (NMIBC) who fail to respond to intravesical BCG is cystectomy. When a patient is deemed BCG-refractory and cannot or will not undergo cystectomy, alternative intravesical therapy may be the most effective way to minimize recurrence and progression. A number of immunotherapeutic and chemotherapeutic agents have been given intravesically over the years, and several recently and currently investigated novel agents appear to be particularly promising for the management of BCG-refractory NMIBC. The most effective treatments in the future will likely utilize targeted therapies based on the underlying genetic mutations associated with each individual diagnosis of NMIBC.

Original language	English (US)
Pages (from-to)	108-111
Number of pages	4
Journal	Urologic Oncology: Seminars and Original Investigations
Volume	28
Issue number	1
DOIs	https://doi.org/10.1016/j.urolonc.2009.03.029
State	Published - Jan 2010

Keywords

BCG-refractory
Bladder cancer
Cystectomy
Intravesical
Novel agents

ASJC Scopus subject areas

Oncology
Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.urolonc.2009.03.029

Cite this

@article{855e51f3158948faa99c1768a54e1e62,

title = "Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG",

abstract = "The definitive treatment for patients with non-muscle-invasive bladder cancer (NMIBC) who fail to respond to intravesical BCG is cystectomy. When a patient is deemed BCG-refractory and cannot or will not undergo cystectomy, alternative intravesical therapy may be the most effective way to minimize recurrence and progression. A number of immunotherapeutic and chemotherapeutic agents have been given intravesically over the years, and several recently and currently investigated novel agents appear to be particularly promising for the management of BCG-refractory NMIBC. The most effective treatments in the future will likely utilize targeted therapies based on the underlying genetic mutations associated with each individual diagnosis of NMIBC.",

keywords = "BCG-refractory, Bladder cancer, Cystectomy, Intravesical, Novel agents",

author = "Barlow, {La Mont J.} and Seager, {Catherine M.} and Benson, {Mitchell C.} and McKiernan, {James M.}",

note = "Funding Information: ☆ LJB and CMS are funded by the Doris Duke Charitable Foundation. ",

year = "2010",

month = jan,

doi = "10.1016/j.urolonc.2009.03.029",

language = "English (US)",

volume = "28",

pages = "108--111",

journal = "Urologic Oncology",

issn = "1078-1439",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG

AU - Barlow, La Mont J.

AU - Seager, Catherine M.

AU - Benson, Mitchell C.

AU - McKiernan, James M.

N1 - Funding Information: ☆ LJB and CMS are funded by the Doris Duke Charitable Foundation.

PY - 2010/1

Y1 - 2010/1

N2 - The definitive treatment for patients with non-muscle-invasive bladder cancer (NMIBC) who fail to respond to intravesical BCG is cystectomy. When a patient is deemed BCG-refractory and cannot or will not undergo cystectomy, alternative intravesical therapy may be the most effective way to minimize recurrence and progression. A number of immunotherapeutic and chemotherapeutic agents have been given intravesically over the years, and several recently and currently investigated novel agents appear to be particularly promising for the management of BCG-refractory NMIBC. The most effective treatments in the future will likely utilize targeted therapies based on the underlying genetic mutations associated with each individual diagnosis of NMIBC.

AB - The definitive treatment for patients with non-muscle-invasive bladder cancer (NMIBC) who fail to respond to intravesical BCG is cystectomy. When a patient is deemed BCG-refractory and cannot or will not undergo cystectomy, alternative intravesical therapy may be the most effective way to minimize recurrence and progression. A number of immunotherapeutic and chemotherapeutic agents have been given intravesically over the years, and several recently and currently investigated novel agents appear to be particularly promising for the management of BCG-refractory NMIBC. The most effective treatments in the future will likely utilize targeted therapies based on the underlying genetic mutations associated with each individual diagnosis of NMIBC.

KW - BCG-refractory

KW - Bladder cancer

KW - Cystectomy

KW - Intravesical

KW - Novel agents

UR - http://www.scopus.com/inward/record.url?scp=72549109957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72549109957&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2009.03.029

DO - 10.1016/j.urolonc.2009.03.029

M3 - Review article

C2 - 20123359

AN - SCOPUS:72549109957

SN - 1078-1439

VL - 28

SP - 108

EP - 111

JO - Urologic Oncology

JF - Urologic Oncology

IS - 1

ER -

Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this